About this Location
UMC anchors academic neurology for the LCMC Health Neuroscience Institute, offering advanced subspecialty care, clinical trials, and research-supported programs for a full range of neurological conditions. The hospital is certified as a Comprehensive Stroke Center and includes LCMC Health’s only Epilepsy Monitoring Unit (EMU) and the system’s first Healthy Brain Aging Initiative.
Conditions Treated At This Location:
- Aneurysm: Diagnosis and treatment for brain aneurysms, including emergency care for ruptures through minimally invasive, endovascular intervention
- Arteriovenous Malformations: Advanced care for abnormal blood vessel connections in the brain, including minimally invasive, endovascular intervention
- Back Pain & Spine: Minimally invasive, surgical, and non-surgical solutions for spine and back conditions
- Brain Tumors: Comprehensive diagnosis and treatment for brain and spinal tumors
- Headaches & Migraines: Evaluation and management for all types of headache disorders, including diagnosis, triggers, and treatments
- Movement Disorders: Care for tremors, dystonia, and other involuntary movement conditions
- Seizures & Epilepsy: Evaluation, testing, and treatment for seizure disorders and epilepsy
- Stroke: Rapid-response stroke care with advanced treatments and outcomes that exceed national benchmarks
Specialty Programs:
- Healthy Brain Aging Initiative: This first-of-its-kind multidisciplinary program in Louisiana addresses both memory and movement disorders, giving patients coordinated access to multiple specialists and comprehensive services—including advanced evaluation, lifestyle and risk-reduction coaching, treatment, support, and clinical trials.
- Neurointervention: Our specialists perform minimally invasive, catheter-based procedures for stroke, aneurysms, and other vascular conditions, providing advanced treatment options and faster recovery times.
Patient Outcomes Data:
2025 carotid procedure outcome data
- UMC's 30-day stroke and death rate for patients following symptomatic CEA, CAS, TCAR for Q1 + Q2 2025 is 4.5% (1 out of 22 cases, goal <6%).
- UMC's 30-day stroke and death rate for patients following asymptomatic CEA, CAS, TCAR for Q1 + Q2 2025 is 0% (0 out of 8 cases; goal <3%).
2024 stroke outcome data
- Mean number of minutes from time of arrival at UMC to start of treatment with clot busting medication: 33 minutes
- Percentage of patients without significant bleeding in the brain following treatment with clot busting medication: 98.2%
- Median number of minutes from time of arrival at UMC to start of treatment with thrombectomy: 103 minutes
- Median number of minutes from the time of arrival at UMC to the time excellent restoration of blood flow is achieved: 127 minutes
- Percentage of patients without significant bleeding in the brain following a thrombectomy procedure: 98.5%
- Percentage of all stroke patients discharged to home or rehab: 74.7%
- Percentage of patients discharged to home or rehab following a thrombectomy procedure: 67%